References
- A.V. Svirid, P.V. Ershov, E.O. Yablokov, L.A. Kaluzhskiy, Y.V. Mezentsev, A.V. Florinskaya, T.A. Sushko, N.V. Strushkevich, A.A. Gilep, S.A. Usanov, A.E. Medvedev, and A.S. Ivanov, Direct molecular fishing of new protein partners for human thromboxane synthase, Acta Naturae 9 (2017), pp. 92–100. doi:https://doi.org/10.32607/20758251-2017-9-4-92-100.
- L.H. Wang and R.J. Kulmacz, Thromboxane synthase: Structure and function of protein and gene, Prostag. Oth. Lipid. M 68-69 (2002), pp. 409–422.
- K.H. Ruan, P. Li, R.J. Kulmacz, and K.K. Wu, Characterization of the structure and membrane interaction of NH2-terminal domain of thromboxane A2 synthase, J. Biol. Chem. 269 (1994), pp. 20938–20942. doi:https://doi.org/10.1016/S0021-9258(17)31912-9.
- L.H. Wang, N. Matijevic-Aleksic, P.Y. Hsu, K.H. Ruan, K.K. Wu, and R.J. Kulmacz, Identification of thromboxane A2 synthase active site residues by molecular modeling-guided site-directed mutagenesis, J. Biol. Chem. 271 (1996), pp. 19970–19975. doi:https://doi.org/10.1074/jbc.271.33.19970.
- N. Nakahata, Thromboxane A2: Physiology/pathophysiology, cellular signal transduction and pharmacology, Pharmacol. Ther. 118 (2008), pp. 18–35. doi:https://doi.org/10.1016/j.pharmthera.2008.01.001.
- P. Fontana, A. Zufferey, Y. Daali, and J.L. Reny, Antiplatelet therapy: Targeting the TxA2 pathway, J. Cardiovasc. Transl. Res. 7 (2014), pp. 29–38. doi:https://doi.org/10.1007/s12265-013-9529-1.
- L. Li, Z.Y. He, Y.Z. Wang, X. Liu, and L.Y. Yuan, Associations between thromboxane A synthase 1 gene polymorphisms and the risk of ischemic stroke in a Chinese Han population, Neural Regen. Res. 13 (2018), pp. 463–469. doi:https://doi.org/10.4103/1673-5374.228729.
- D.F. Mesitskaya, A.L. Syrkin, M.G. Aksenova, Y. Zhang, A.A. Zamyatnin Jr., and P.Y. Kopylov, Thromboxane A synthase: A new target for the treatment of cardiovascular diseases, Cardiovasc. Hematol. Agents Med. Chem. 16 (2018), pp. 81–87. doi:https://doi.org/10.2174/1871525716666180724115132.
- S.H. Oh, Y.H. Kim, S.M. Park, S.H. Cho, J.S. Park, A.S. Jang, S.W. Park, S.T. Uh, Y.M. Lee, M.K. Kim, I.S. Choi, S.H. Cho, C.S. Hong, Y.W. Lee, J.Y. Lee, B.W. Choi, B.L. Park, H.D. Shin, and C.S. Park, Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients, Pharmacogenomics 12 (2011), pp. 351–363. doi:https://doi.org/10.2217/pgs.10.181.
- M.C. Cathcart, J.V. Reynolds, K.J. O’Byrne, and G.P. Pidgeon, The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer, Biochim. Biophys. Acta 1805 (2010), pp. 153–166. doi:https://doi.org/10.1016/j.bbcan.2010.01.006.
- P. Ekambaram, W. Lambiv, R. Cazzolli, A.W. Ashton, and K.V. Honn, The thromboxane synthase and receptor signaling pathway in cancer: An emerging paradigm in cancer progression and metastasis, Cancer Metast. Rev. 30 (2011), pp. 397–408. doi:https://doi.org/10.1007/s10555-011-9297-9.
- R.Y. Huang and G.G. Chen, Cigarette smoking, cyclooxygenase-2 pathway and cancer, Biochim. Biophys. Acta 1815 (2011), pp. 158–169. doi:https://doi.org/10.1016/j.bbcan.2010.11.005.
- K.C. Leung, M.Y. Li, B.C. Leung, M.K. Hsin, T.S. Mok, M.J. Underwood, and G.G. Chen, Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-kappaB, Exp. Cell Res. 316 (2010), pp. 3468–3477. doi:https://doi.org/10.1016/j.yexcr.2010.07.003.
- O. Moussa, J.M. Riker, J. Klein, M. Fraig, P.V. Halushka, and D.K. Watson, Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents, Oncogene 27 (2008), pp. 55–62. doi:https://doi.org/10.1038/sj.onc.1210629.
- H. Sakai, T. Suzuki, Y. Takahashi, M. Ukai, K. Tauchi, T. Fujii, N. Horikawa, T. Minamimura, Y. Tabuchi, M. Morii, K. Tsukada, and N. Takeguchi, Upregulation of thromboxane synthase in human colorectal carcinoma and the cancer cell proliferation by thromboxane A2, FEBS Lett. 580 (2006), pp. 3368–3374. doi:https://doi.org/10.1016/j.febslet.2006.05.007.
- L. Plantureux, D. Mege, L. Crescence, F. Dignat-George, C. Dubois, and L. Panicot-Dubois, Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis, Cancers (Basel) 10 (2018), pp. 1–23. doi:https://doi.org/10.3390/cancers10110441.
- R.Y. Huang, Y.L. Chu, Z.B. Jiang, X.M. Chen, X. Zhang, and X. Zeng, Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase, Cell. Physiol. Biochem. 33 (2014), pp. 375–388. doi:https://doi.org/10.1159/000356677.
- T. Tanouchi, M. Kawamura, I. Ohyama, I. Kajiwara, Y. Iguchi, T. Okada, T. Miyamoto, K. Taniguchi, M. Hayashi, K. Iizuka, and M. Nakazawa, Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives, J. Med. Chem. 24 (1981), pp. 1149–1155.
- K. Iizuka, K. Akahane, D. Momose, M. Nakazawa, T. Tanouchi, M. Kawamura, I. Ohyama, I. Kajiwara, Y. Iguchi, T. Okada, K. Taniguchi, T. Miyamoto, and M. Hayashi, Highly selective inhibitors of thromboxane synthetase. 1. Imidazole derivatives, J. Med. Chem. 24 (1981), pp. 1139–1148.
- K. Kato, S. Ohkawa, S. Terao, Z. Terashita, and K. Nishikawa, Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids, J. Med. Chem. 28 (1985), pp. 287–294. doi:https://doi.org/10.1021/jm00381a005.
- O. Uyama, K. Nagatsuka, S. Nakabayashi, Y. Isaka, S. Yoneda, K. Kimura, and H. Abe, The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease, Stroke 16 (1985), pp. 241–244. doi:https://doi.org/10.1161/01.STR.16.2.241.
- N. Hamanaka, K. Takahashi, Y. Nagao, K. Torisu, S. Shigeoka, S. Hamada, H. Kato, H. Tokumoto, and K. Kondo, Pharmacological evaluation of combined PGI 2 agonists/thromboxane synthase inhibitors. I, Bioorg. Med. Chem. Lett. 5 (1995), pp. 1087–1090. doi:https://doi.org/10.1016/0960-894X(95)00171-O.
- G. Davi, F. Santilli, and N. Vazzana, Thromboxane receptors antagonists and/or synthase inhibitors, Handb. Exp. Pharmacol. 210 (2012), pp. 261–286.
- P.E. Cross, R.P. Dickinson, M.J. Parry, and M.J. Randall, Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles, J. Med. Chem. 28 (1985), pp. 1427–1432. doi:https://doi.org/10.1021/jm00148a009.
- P.S. Kiff, G. Bergman, L. Atkinson, D.E. Jewitt, J. Westwick, and V.V. Kakkar, Haemodynamic and metabolic effects of dazoxiben at rest and during atrial pacing, Br. J. Clin. Pharmacol. 15 (1983), pp. 73S–77S. doi:https://doi.org/10.1111/j.1365-2125.1983.tb02112.x.
- E. Thaulow, J. Dale, and E. Myhre, Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease, Am. J. Cardiol. 53 (1984), pp. 1255–1258. doi:https://doi.org/10.1016/0002-9149(84)90074-2.
- G.A. FitzGerald, I.A. Reilly, and A.K. Pedersen, The biochemical pharmacology of thromboxane synthase inhibition in man, Circulation 72 (1985), pp. 1194–1201. doi:https://doi.org/10.1161/01.CIR.72.6.1194.
- Yaozh: A database of drugs. Available at https://www.yaozh.com/ (accessed September, 2021).
- Y. Amemiya, A. Terada, K. Wachi, H. Miyazawa, N. Hatakeyama, K. Matsuda, and T. Oshima, Synthesis and thromboxane synthetase inhibitory activity of di- or tetrahydrobenzo[b]thiophenecarboxylic acid derivatives, J. Med. Chem. 32 (1989), pp. 1265–1272. doi:https://doi.org/10.1021/jm00126a020.
- P.A. Modesti, A. Colella, R. Abbate, G. Gensini, and G. Neri Serneri, Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide, Eur. J. Pharmacol. 169 (1989), pp. 85–93. doi:https://doi.org/10.1016/0014-2999(89)90820-0.
- B. Li, R. Huang, R. Wang, Y. Liu, C.G. Stief, and M. Hennenberg, Picotamide inhibits a wide spectrum of agonist-induced smooth muscle contractions in porcine renal interlobar and coronary arteries, Pharmacol. Res. Perspect. 9 (2021), pp. e00771. doi:https://doi.org/10.1002/prp2.771.
- M. De Carlo, G. Di Minno, T. Sayre, M.S. Fazeli, G. Siliman, and C. Cimminiello, Efficacy and safety of antiplatelet therapies in symptomatic peripheral artery disease: A systematic review and network meta-analysis, Curr. Vasc. Pharmacol. 19 (2021), pp. 542–555. doi:https://doi.org/10.2174/1570161118666200820141131.
- A.N. Sharma, J.S. Deyell, S.N. Sharma, and A. Barseghian, Role of and recent evidence for antiplatelet therapy in prevention of cardiovascular disease in diabetes, Curr. Cardiol. Rep. 21 (2019), pp. 1–9. doi:https://doi.org/10.1007/s11886-019-1168-y.
- P.A. Modesti, I. Cecioni, A. Colella, A. Costoli, R. Paniccia, and G.G. Neri Serneri, Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist, Br. J. Pharmacol. 112 (1994), pp. 81–86. doi:https://doi.org/10.1111/j.1476-5381.1994.tb13033.x.
- B.D. Guth, H. Narjes, H.D. Schubert, P. Tanswell, A. Riedel, and G. Nehmiz, Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects, Br. J. Clin. Pharmacol. 58 (2004), pp. 40–51. doi:https://doi.org/10.1111/j.1365-2125.2004.02083.x.
- R. Soyka, B.D. Guth, H.M. Weisenberger, P. Luger, and T.H. Muller, Guanidine derivatives as combined thromboxane A 2 receptor antagonists and synthase inhibitors, J. Med. Chem. 42 (1999), pp. 1235–1249. doi:https://doi.org/10.1021/jm9707941.
- A. Bender and I. Cortes-Ciriano, Artificial intelligence in drug discovery: What is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet, Drug Discov. Today 26 (2021), pp. 511–524. doi:https://doi.org/10.1016/j.drudis.2020.12.009.
- E.N. Muratov, J. Bajorath, R.P. Sheridan, I.V. Tetko, D. Filimonov, V. Poroikov, T.I. Oprea, I.I. Baskin, A. Varnek, A. Roitberg, O. Isayev, S. Curtarolo, D. Fourches, Y. Cohen, A. Aspuru-Guzik, D.A. Winkler, D. Agrafiotis, A. Cherkasov, and A. Tropsha, QSAR without borders (vol 10, pg 531, 2020), Chem. Soc. Rev. 49 (2020), pp. 3716. doi:https://doi.org/10.1039/D0CS90041A.
- P.P. Mager, Molecular simulation of chemical structure and biological activity of thromboxane synthase inhibitors by multivariate neural-network analysis, Mol. Simulat. 29 (2003), pp. 71–75. doi:https://doi.org/10.1080/0892702031000065746.
- C. Kontogiorgis and D. Hadjipavlou-Litina, Thromboxane synthase inhibitors and thromboxane A2 receptor antagonists: A quantitative structure activity relationships (QSARs) analysis, Curr. Med. Chem. 17 (2010), pp. 3162–3214. doi:https://doi.org/10.2174/092986710792231978.
- K.V. Tambov, I.V. Voevodina, A.V. Manaev, Y.A. Ivanenkov, N. Neamati, and V.F. Traven, Structures and biological activity of cinnamoyl derivatives of coumarins and dehydroacetic acid and their boron difluoride complexes, Russ. Chem. B+ 61 (2012), pp. 78–90. doi:https://doi.org/10.1007/s11172-012-0012-y.
- Reaxys: A database of biochemical information about compounds. Available at https://www.reaxys.com/ (accessed September, 2021).
- ChEMBL: A database of bioactive molecules with drug-like properties. Available at https://www.ebi.ac.uk/chembl/ (accessed September, 2021).
- P.E. Cross, R.P. Dickinson, M.J. Parry, and M.J. Randall, Selective thromboxane synthetase inhibitors. 4. 2-(1H-imidazol-1-ylmethyl) carboxylic acids of benzo[b]furan, benzo[b]thiophene, indole, and naphthalene, J. Med. Chem. 29 (1986), pp. 1643–1650. doi:https://doi.org/10.1021/jm00159a013.
- P.E. Cross, R.P. Dickinson, M.J. Parry, and M.J. Randall, Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues, J. Med. Chem. 29 (1986), pp. 342–346. doi:https://doi.org/10.1021/jm00153a007.
- P.E. Cross, R.P. Dickinson, M.J. Parry, and M.J. Randall, Selective thromboxane synthetase inhibitors. 3. 1H-imidazol-1-yl-substituted benzo[b]furan-, benzo[b]thiophene-, and indole-2- and −3-carboxylic acids, J. Med. Chem. 29 (1986), pp. 1637–1643. doi:https://doi.org/10.1021/jm00159a012.
- P.W. Sprague, J.E. Heikes, J.Z. Gougoutas, M.F. Malley, D.N. Harris, and R. Greenberg, Synthesis and in vitro pharmacology of 7-oxabicyclo[2.2.1]heptane analogues of thromboxane A2/PGH2, J. Med. Chem. 28 (1985), pp. 1580–1590. doi:https://doi.org/10.1021/jm00149a007.
- N.F. Ford, L.J. Browne, T. Campbell, C. Gemenden, R. Goldstein, C. Gude, and J.W. Wasley, Imidazo[1,5-a]pyridines: A new class of thromboxane A2 synthetase inhibitors, J. Med. Chem. 28 (1985), pp. 164–170. doi:https://doi.org/10.1021/jm00380a003.
- P.W. Manley, N.M. Allanson, R.F. Booth, P.E. Buckle, E.J. Kuzniar, N. Lad, S.M. Lai, D.O. Lunt, and D.P. Tuffin, Structure-activity relationships in an imidazole-based series of thromboxane synthase inhibitors, J. Med. Chem. 30 (1987), pp. 1588–1595. doi:https://doi.org/10.1021/jm00392a011.
- J.W. Tilley, P. Levitan, J. Lind, A.F. Welton, H.J. Crowley, L.D. Tobias, and M. O’Donnell, N-(heterocyclic alkyl)pyrido[2,1-b]quinazoline-8-carboxamides as orally active antiallergy agents, J. Med. Chem. 30 (1987), pp. 185–193. doi:https://doi.org/10.1021/jm00384a031.
- A.J. Main, S.S. Bhagwat, C. Boswell, R. Goldstein, C. Gude, D.S. Cohen, P. Furness, W. Lee, and M. Louzan, Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids, J. Med. Chem. 35 (1992), pp. 4366–4372. doi:https://doi.org/10.1021/jm00101a014.
- S.S. Bhagwat, C. Gude, D.S. Cohen, W. Lee, P. Furness, and F.H. Clarke, Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (±)-(3-pyridinylbicycloheptyl)alkanoic acids, J. Med. Chem. 34 (1991), pp. 1790–1797. doi:https://doi.org/10.1021/jm00110a006.
- A.J. Main, R. Goldstein, D.S. Cohen, P. Furness, and W. Lee, Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 2. Synthesis and biological activity of 8-(benzenesulfonamido)-7-(3-pyridinyl)octaonic acid and related compounds, J. Med. Chem. 35 (1992), pp. 4362–4365. doi:https://doi.org/10.1021/jm00101a013.
- S.S. Bhagwat, C. Gude, C. Boswell, N. Contardo, D.S. Cohen, R. Dotson, J. Mathis, W. Lee, P. Furness, and H. Zoganas, Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 4. 8-[[(4-Chlorophenyl)sulfonyl]amino]-4-(3-(3-pyridinyl) propyl)octanoic acid and analogs, J. Med. Chem. 35 (1992), pp. 4373–4383. doi:https://doi.org/10.1021/jm00101a015.
- M. Yamaguchi, K. Kamei, T. Koga, M. Akima, A. Maruyama, T. Kuroki, and N. Ohi, Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 2. 4-(3-Pyridyl)-1(2H)-phthalazinones, J. Med. Chem. 36 (1993), pp. 4061–4068. doi:https://doi.org/10.1021/jm00077a009.
- S.S. Bhagwat, C. Gude, D.S. Cohen, R. Dotson, J. Mathis, W. Lee, and P. Furness, Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 5. Synthesis and evaluation of enantiomers of 8-[[(4-chlorophenyl)sulfonyl]amino]-4-(3-pyridinylalkyl)octanoic acid, J. Med. Chem. 36 (1993), pp. 205–210. doi:https://doi.org/10.1021/jm00054a003.
- S. Hibi, Y. Okamoto, K. Tagami, H. Numata, N. Kobayashi, M. Shinoda, T. Kawahara, M. Murakami, K. Oketani, T. Inoue et al., Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: Synthesis and structure-activity relationships of 3-pyridylmethyl-substituted2-amino-6-hydroxybenzothiazole derivatives, J. Med. Chem. 37 (1994), pp. 3062–3070. doi:https://doi.org/10.1021/jm00045a011.
- G.M. Ksander, M. Erion, A.M. Yuan, C.G. Diefenbacher, L. el-Chehabi, D. Cote, and N. Levens, Dual angiotensin converting enzyme/thromboxane synthase inhibitors, J. Med. Chem. 37 (1994), pp. 1823–1832. doi:https://doi.org/10.1021/jm00038a011.
- A.W. Faull, A.G. Brewster, G.R. Brown, M.J. Smithers, and R. Jackson, Dual-acting thromboxane receptor antagonist/synthase inhibitors: Synthesis and biological properties of [2-substituted-4-(3-pyridyl)-1,3-dioxan-5-yl] alkenoic acids, J. Med. Chem. 38 (1995), pp. 686–694. doi:https://doi.org/10.1021/jm00004a014.
- N. Ackerley, A.G. Brewster, G.R. Brown, D.S. Clarke, A.J. Foubister, S.J. Griffin, J.A. Hudson, M.J. Smithers, and P.R. Whittamore, A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors, J. Med. Chem. 38 (1995), pp. 1608–1628. doi:https://doi.org/10.1021/jm00010a005.
- R.P. Dickinson, K.N. Dack, C.J. Long, and J. Steele, Thromboxane modulating agents. 3. ylalkyl 1 H -Imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted [(arylsulfonyl)amino]ethyl] benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists, J. Med. Chem. 40 (1997), pp. 3442–3452. doi:https://doi.org/10.1021/jm9702793.
- M. Fujita, T. Seki, H. Inada, K. Shimizu, A. Takahama, and T. Sano, Approach to dual-acting platelet activating factor (PAF) receptor antagonist/thromboxane synthase inhibitor (TxSI) based on the link of PAF antagonists and TxSIs, Bioorg. Med. Chem. Lett. 12 (2002), pp. 341–344. doi:https://doi.org/10.1016/S0960-894X(01)00731-4.
- M. Fujita and T. Seki, Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI), Bioorg. Med. Chem. Lett. 12 (2002), pp. 1383–1386. doi:https://doi.org/10.1016/S0960-894X(02)00186-5.
- R.P. Dickinson, K.N. Dack, J. Steele, and M.S. Tute, Thromboxane modulating agents. 2. Thromboxane receptor antagonists derived from the thromboxane synthase inhibitor dazmegrel, Bioorg. Med. Chem. Lett. 6 (1996), pp. 1691–1696. doi:https://doi.org/10.1016/0960-894X(96)00299-5.
- R.P. Dickinson, K.N. Dack, and J. Steele, Thromboxane modulating agents. 1. Design of 1-[(arylsulfonyl)amino] alkylindole derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists, Bioorg. Med. Chem. Lett. 5 (1995), pp. 3017–3022. doi:https://doi.org/10.1016/0960-894X(95)00529-4.
- K. Russell, H. Gaskin, and R. Jessup, Discovery of dual activity molecules with thromboxane antagonist and thromboxane synthase inhibitory activity, Bioorg. Med. Chem. Lett. 2 (1992), pp. 979–984. doi:https://doi.org/10.1016/S0960-894X(00)80601-0.
- G.R. Brown, D.S. Clarke, A.W. Faull, A.J. Foubister, and M.J. Smithers, Design of dual-acting thromboxane antagonist-synthase inhibitors by a mutual prodrug approach, Bioorg. Med. Chem. Lett. 6 (1996), pp. 273–278. doi:https://doi.org/10.1016/0960-894X(96)00004-2.
- M. Fujita, T. Seki, H. Inada, K. Shimizu, and T. Sano, Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI), Bioorg. Med. Chem. Lett. 12 (2002), pp. 771–774. doi:https://doi.org/10.1016/S0960-894X(02)00005-7.
- D. Riendeau, R. Aspiotis, D. Ethier, Y. Gareau, E.L. Grimm, J. Guay, S. Guiral, H. Juteau, J.A. Mancini, N. Methot, J. Rubin, and R.W. Friesen, Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886, Bioorg. Med. Chem. Lett. 15 (2005), pp. 3352–3355. doi:https://doi.org/10.1016/j.bmcl.2005.05.027.
- R. Morphy and Z. Rankovic, Designed multiple ligands. An emerging drug discovery paradigm, J. Med. Chem. 48 (2005), pp. 6523–6543. doi:https://doi.org/10.1021/jm058225d.
- B. Cote, L. Boulet, C. Brideau, D. Claveau, D. Ethier, R. Frenette, M. Gagnon, A. Giroux, J. Guay, S. Guiral, J. Mancini, E. Martins, F. Masse, N. Methot, D. Riendeau, J. Rubin, D. Xu, H. Yu, Y. Ducharme, and R.W. Friesen, Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 6816–6820. doi:https://doi.org/10.1016/j.bmcl.2007.10.033.
- S.S. Bhagwat, C. Boswell, C. Gude, N. Contardo, and S. Shetty, Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 6. 4-substituted 3-pyridinylalkanoic acids, Bioorg. Med. Chem. Lett. 2 (1992), pp. 1619–1622. doi:https://doi.org/10.1016/S0960-894X(00)80442-4.
- S.S. Bhagwat, D.M. Roland, A.J. Main, C. Gude, K. Grim, R. Goldstein, D.S. Cohen, R. Dotson, J. Mathis, and W. Lee, Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 7. pyridinylalkyl-substituted arylsulfonylamino arylalkanoic acids, Bioorg. Med. Chem. Lett. 2 (1992), pp. 1623–1626. doi:https://doi.org/10.1016/S0960-894X(00)80443-6.
- A. Giroux, L. Boulet, C. Brideau, A. Chau, D. Claveau, B. Cote, D. Ethier, R. Frenette, M. Gagnon, J. Guay, S. Guiral, J. Mancini, E. Martins, F. Masse, N. Methot, D. Riendeau, J. Rubin, D. Xu, H. Yu, Y. Ducharme, and R.W. Friesen, Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors, Bioorg. Med. Chem. Lett. 19 (2009), pp. 5837–5841. doi:https://doi.org/10.1016/j.bmcl.2009.08.085.
- T. Shiro, K. Kakiguchi, H. Takahashi, H. Nagata, and M. Tobe, 7-Phenyl-imidazoquinolin-4(5H)-one derivatives as selective and orally available mPGES-1 inhibitors, Bioorg. Med. Chem. 21 (2013), pp. 2868–2878. doi:https://doi.org/10.1016/j.bmc.2013.03.069.
- S.T. Kam, P.S. Portoghese, J.M. Gerrard, and E.W. Dunham, Synthesis and biological evaluation of 9,11-azo-13-oxa-15-hydroxyprostanoic acid, a potent inhibitor of platelet aggregation, J. Med. Chem. 22 (1979), pp. 1402–1408. doi:https://doi.org/10.1021/jm00197a023.
- Y. Satoh, J.L. Stanton, A.J. Hutchison, A.H. Libby, T.J. Kowalski, W.H. Lee, D.H. White, and E.F. Kimble, Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors, J. Med. Chem. 36 (1993), pp. 3580–3594. doi:https://doi.org/10.1021/jm00075a013.
- K.N. Dack, R.P. Dickinson, C.J. Long, and J. Steele, Thromboxane modulating agents. 4. Design and synthesis of 3-(2-[{(4-chlorophenyl)sulfonyl}amino]ethyl)benzenepropanoic acid derivatives as potent thromboxane receptor antagonists, Bioorg. Med. Chem. Lett. 8 (1998), pp. 2061–2066. doi:https://doi.org/10.1016/S0960-894X(98)00242-X.
- A. Faull, H. Gaskin, P. Hadfield, R. Jessup, K. Russell, W. Watkins, and M. Wayne, Dual-acting thromboxane receptor antagonist/synthase inhibitors: Heterocyclic variations, Bioorg. Med. Chem. Lett. 2 (1992), pp. 1181–1186. doi:https://doi.org/10.1016/S0960-894X(00)80210-3.
- I. Vlattas, J. Dellureficio, D. Cohen, W. Lee, F. Clarke, R. Dotson, J. Mathis, and H. Zoganas, Oxa-prostanoid analogs. Identification of an orally effective, dual thromboxane receptor antagonist /thromboxane synthase inhibitor, Bioorg. Med. Chem. Lett. 4 (1994), pp. 2073–2076. doi:https://doi.org/10.1016/S0960-894X(01)80104-9.
- I. Vlattas, J. Dellureficio, D.S. Cohen, W. Lee, F. Clarke, R. Dotson, J. Mathis, and H. Zoganas, Thia-prostanoid analogs with combined thromboxane receptor antagonist/thromboxane synthase inhibitor activities. Synthesis and pharmacological evaluation, Bioorg. Med. Chem. Lett. 4 (1994), pp. 2067–2072. doi:https://doi.org/10.1016/S0960-894X(01)80103-7.
- H. Sakai, T. Suzuki, M. Murota, K. Oketani, T. Uchiumi, M. Murakami, and N. Takeguchi, E3040 sulphate, a novel thromboxane synthase inhibitor, blocks the Cl − secretion induced by platelet-activating factor in isolated rat colon, Br. J. Pharmacol. 136 (2002), pp. 383–390. doi:https://doi.org/10.1038/sj.bjp.0704723.
- K. Oketani, N. Nagakura, K. Harada, and T. Inoue, In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production, Eur. J. Pharmacol. 422 (2001), pp. 209–216. doi:https://doi.org/10.1016/S0014-2999(01)01022-6.
- H.H. Tai and B. Yuan, On the inhibitory potency of imidazole and its derivatives on thromboxane synthetase, Biochem. Biophys. Res. Commun. 80 (1978), pp. 236–242. doi:https://doi.org/10.1016/0006-291X(78)91128-2.
- E.C. Ku, S.E. Mcpherson, C. Signor, H. Chertock, and W.D. Cash, Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models, Biochem. Bioph. Res. Co. 112 (1983), pp. 899–906. doi:https://doi.org/10.1016/0006-291X(83)91702-3.
- D.N. Harris, R. Greenberg, M.B. Phillips, I.M. Michel, H.J. Goldenberg, M.F. Haslanger, and T.E. Steinbacher, Effects of SQ 27,427, a thromboxane A2 receptor antagonist, in the human platelet and isolated smooth muscle, Eur. J. Pharmacol. 103 (1984), pp. 9–18. doi:https://doi.org/10.1016/0014-2999(84)90183-3.
- H. Mikashima, H. Ochi, Y. Muramoto, H. Yasuda, M. Tsuruta, and Y. Maruyama, Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function, Thromb. Res. 43 (1986), pp. 455–468. doi:https://doi.org/10.1016/0049-3848(86)90090-3.
- B. Lee, K. Takasaki, A. Mochizuki, N. Tamura, Y. Higashide, and T. Yamaura, [Pharmacological profiles of F-1322, a novel anti-asthmatic agent. (1). Mechanisms of action], Nippon Yakurigaku Zasshi 106 (1995), pp. 31–40. doi:https://doi.org/10.1254/fpj.106.31.
- S. Sakurai, N. Ogawa, T. Suzuki, K. Kato, T. Ohashi, S. Yasuda, and H. Kato, Synthesis of [[(benzenesulfonamido)alkyl]phenyl]alkanoic acid derivatives containing pyridyl or imidazolyl groups and their thromboxane A2 receptor antagonistic and thromboxane A2 synthase inhibitory activities, Chem. Pharm. Bull. (Tokyo) 44 (1996), pp. 1510–1520. doi:https://doi.org/10.1248/cpb.44.1510.
- S. Hibi, Y. Okamoto, K. Tagami, H. Numata, N. Kobayashi, M. Shinoda, T. Kawahara, K. Harada, K. Miyamoto, and I. Yamatsu, Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase, J. Med. Chem. 39 (1996), pp. 3148–3157. doi:https://doi.org/10.1021/jm950725r.
- T. Ishizuka, DP-1904: A novel specific TXA2 synthetase inhibitor, Cardiovasc. Drug. Rev. 15 (1997), pp. 27–43. doi:https://doi.org/10.1111/j.1527-3466.1997.tb00322.x.
- R.P. Dickinson, K.N. Dack, and J. Steele, Pyridine derived agents for cardiovascular diseases, Patent No. US 5457118, 1995.
- G.R. Brown, A.W. Faull, A.G. Brewster, M.J. Smithers, and R. Jessup, 4-pyridyl-1,3-dioxane derivatives, Patent No. US 5401849, 1995.
- A.W. Faull, K. Russell, and W.J. Watkins, Heterocyclic acids, Patent No. US 5219874, 1993.
- A.G. Brewster, G.R. Brown, A.W. Faull, R. Jessup, and M.J. Smithers, Pyridyl substituted alkenoic acid derivatives, Patent No. US 5248780, 1993.
- A.G. Brewster, R. Jessup, M.J. Smithers, G.R. Brown, and A.W. Faull, Pyridine derivatives, Patent No. US 5053415, 1991.
- A.G. Brewster, M.J. Smithers, G.R. Brown, and R. Jessup, 1,3-dioxanes, Patent No. US 4921866, 1990.
- Y. Ito, H. Kato, S. Yasuda, N. Ogawa, T. Suzuki, and S. Sakurai, Benzenesulfonamide derivatives and use thereof, Patent No. US 5597848, 1997.
- D.H. Lee, H.W. Kwon, H.H. Kim, D.H. Lim, G.S. Nam, J.H. Shin, Y.Y. Kim, J.L. Kim, J.J. Lee, H.K. Kwon, and H.J. Park, Cordycepin-enriched WIB801C from Cordyceps militaris inhibits ADP-induced [Ca(2+)] i mobilization and fibrinogen binding via phosphorylation of IP 3R and VASP, Arch. Pharm. Res. 38 (2015), pp. 81–97. doi:https://doi.org/10.1007/s12272-014-0436-z.
- M. Hecker, M. Haurand, V. Ullrich, and S. Terao, Spectral studies on structure-activity relationships of thromboxane synthase inhibitors, Eur. J. Biochem. 157 (1986), pp. 217–223. doi:https://doi.org/10.1111/j.1432-1033.1986.tb09659.x.
- P.E. Cross, R.P. Dickinson, M.J. Parry, and M.J. Randall, 3-(1-imidazolylmethyl) indoles: Potent and selective inhibitors of human blood platelet thromboxane synthetase, Agents Actions 11 (1981), pp. 274–280. doi:https://doi.org/10.1007/BF01967626.
- N. Kase, K. Takasaki, Y. Higashide, N. Tamura, B. Lee, T. Yamaura, and H. Ohnishi, [Pharmacological profile of F-0401, a novel dihydropyridine derivative. (1) Mechanisms of action], Nippon Yakurigaku Zasshi 101 (1993), pp. 363–374. doi:https://doi.org/10.1254/fpj.101.6_363.
- R.P. Brownlie, N.J. Brownrigg, H.M. Butcher, R. Garcia, R. Jessup, V.J. Lee, S. Tunstall, and M.G. Wayne, ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog, J. Pharm. Pharmacol. 49 (1997), pp. 187–194. doi:https://doi.org/10.1111/j.2042-7158.1997.tb06777.x.
- J. Daemmgen, J.V. Ryn, M. Pairet, and B. Guth, Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a COX-2 inhibitor Patent No. US 20060217431, 2006.
- T. Kohonen, Self-organized formation of topologically correct feature maps, Biol. Cybern. 43 (1982), pp. 59–69. doi:https://doi.org/10.1007/BF00337288.
- SONNIA: Self-Organizing Neural Network Package. Available at https://www.mn-am.com/products/%0Asonnia. (accessed September, 2021).
- A. Givehchi and G. Schneider, Impact of descriptor vector scaling on the classification of drugs and nondrugs with artificial neural networks, J. Mol. Model. 10 (2004), pp. 204–211. doi:https://doi.org/10.1007/s00894-004-0186-9.
- S. Zhang, Y. Li, Z. Qin, G. Tu, G. Chen, and A. Yan, SAR study on inhibitors of GIIA secreted phospholipase A2 using machine learning methods, Chem. Biol. Drug Des. 93 (2019), pp. 666–684. doi:https://doi.org/10.1111/cbdd.13470.
- S. Riniker and G.A. Landrum, Open-source platform to benchmark fingerprints for ligand-based virtual screening, J. Cheminform. 5 (2013), pp. 1–26. doi:https://doi.org/10.1186/1758-2946-5-26.
- D. Rogers and M. Hahn, Extended-connectivityfingerprints, J. Chem. Inf. Model. 50 (2010), pp. 742–754. doi:https://doi.org/10.1021/ci100050t.
- Molecular Operating Environment (MOE), 2015.10; Chemical Computing Group Inc., 1010 Sherbrooe St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2015.
- RDKit: Open-source cheminformatics software. Available at http://www.rdkit.org. (accessed October, 2021).
- A.T. Balaban, Five new topological indices for the branching of tree-like graphs, Theor. Chim. Acta 53 (1979), pp. 355–375. doi:https://doi.org/10.1007/BF00555695.
- A.T. Balaban, Highly discriminating distance-based topological index, Chem. Phys. Lett. 89 (1982), pp. 399–404. doi:https://doi.org/10.1016/0009-2614(82)80009-2.
- P. Ertl, B. Rohde, and P. Selzer, Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties, J. Med. Chem. 43 (2000), pp. 3714–3717. doi:https://doi.org/10.1021/jm000942e.
- J. Gasteiger and M. Marsili, Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges, Tetrahedron 36 (1980), pp. 3219–3228. doi:https://doi.org/10.1016/0040-4020(80)80168-2.
- P.R. Gerber, Charge distribution from a simple molecular orbital type calculation and non-bonding interaction terms in the force field MAB, J. Comput. Aided Mol. Des. 12 (1998), pp. 37–51. doi:https://doi.org/10.1023/A:1007902804814.
- L.H. Hall and L.B. Kier, The molecular connectivity chi indexes and kappa shape indexes in structure‐property modeling, Rev. Comp. Chem. 2 (1991), pp. 367–422.
- T.J. Hou, K. Xia, W. Zhang, and X.J. Xu, ADME evaluation in drug discovery. 4. Prediction of aqueous solubility based on atom contribution approach, J. Chem. Inf. Comput. Sci. 44 (2004), pp. 266–275. doi:https://doi.org/10.1021/ci034184n.
- J. Kazius, R. McGuire, and R. Bursi, Derivation and validation of toxicophores for mutagenicity prediction, J. Med. Chem. 48 (2005), pp. 312–320. doi:https://doi.org/10.1021/jm040835a.
- L.B. Kier and L.H. Hall, The nature of structure-activity relationships and their relation to molecular connectivity, Eur. J. Med. Chem. 12 (1977), pp. 307–312.
- P. Labute, A widely applicable set of descriptors, J. Mol. Graph Model 18 (2000), pp. 464–477. doi:https://doi.org/10.1016/S1093-3263(00)00068-1.
- D.R. Lide, CRC Handbook of Chemistry and Physics, Am. J. Med. Sci. 257 (1969), pp. 423. doi:https://doi.org/10.1097/00000441-196906000-00020.
- C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1, Adv. Drug Deliver. Rev. 46 (2001), pp. 3–26. doi:https://doi.org/10.1016/S0169-409X(00)00129-0.
- T.I. Oprea, Property distribution of drug-related chemical databases, J. Comput. Aided Mol. Des. 14 (2000), pp. 251–264. doi:https://doi.org/10.1023/A:1008130001697.
- M. Petitjean, Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds, J. Chem. Inf. Model. 32 (1992), pp. 331–337.
- H. Wiener, Structural determination of paraffin boiling points, J. Am. Chem. Soc. 69 (1947), pp. 17–20. doi:https://doi.org/10.1021/ja01193a005.
- S.A. Wildman and G.M. Crippen, Prediction of physicochemical parameters by atomic contributions, J. Chem. Inf. Comp. Sci. 39 (1999), pp. 868–873. doi:https://doi.org/10.1021/ci990307l.
- G. Cruciani, P. Crivori, P.A. Carrupt, and B. Testa, Molecular fields in quantitative structure–permeation relationships: The VolSurf approach, J. Mol. Struc. Theochem 503 (2000), pp. 17–30. doi:https://doi.org/10.1016/S0166-1280(99)00360-7.
- W.H.B. Sauer and M.K. Schwarz, Molecular shape diversity of combinatorial libraries: A prerequisite for broad bioactivity, J. Chem. Inf. Model. 43 (2003), pp. 987–1003.
- D.T. Stanton and P.C. Jurs, Development and use of charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies, Anal. Chem. 62 (1990), pp. 2323–2329. doi:https://doi.org/10.1021/ac00220a013.
- S.M. Lundberg and S.I. Lee, A unified approach to interpreting model predictions, Adv. Neural Inf. Process. Syst. 30 (2017), pp. 4768–4777.
- SPSS Inc. Released. PASW Statistics for Windows, Version 18.0, SPSS Inc, Chicago, 2009.
- V.G. Maltarollo, T. Kronenberger, G.Z. Espinoza, P.R. Oliveira, and K.M. Honorio, Advances with support vector machines for novel drug discovery, Expert Opin. Drug Dis. 14 (2019), pp. 23–33. doi:https://doi.org/10.1080/17460441.2019.1549033.
- P.G. Polishchuk, E.N. Muratov, A.G. Artemenko, O.G. Kolumbin, N.N. Muratov, and V.E. Kuz’min, Application of random forest approach to qsar prediction of aquatic toxicity, J. Chem. Inf. Model. 49 (2009), pp. 2481–2488. doi:https://doi.org/10.1021/ci900203n.
- I.B. Mustapha and F. Saeed, Bioactive molecule prediction using extreme gradient boosting, Molecules 21 (2016), pp. 1–11.
- J.S. Ma, R.P. Sheridan, A. Liaw, G.E. Dahl, and V. Svetnik, Deep neural nets as a method for quantitative structure-activity relationships, J. Chem. Inf. Model. 55 (2015), pp. 263–274. doi:https://doi.org/10.1021/ci500747n.
- K. Tanabe, T. Kurita, K. Nishida, B. Lucic, D. Amic, and T. Suzuki, Improvement of carcinogenicity prediction performances based on sensitivity analysis in variable selection of SVM models, SAR QSAR Environ. Res. 24 (2013), pp. 565–580. doi:https://doi.org/10.1080/1062936X.2012.762425.
- F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss, V. Dubourg, J. Vanderplas, A. Passos, D. Cournapeau, M. Brucher, M. Perrot, and E. Duchesnay, Scikit-learn: Machine learning in Python, J. Mach. Learn. Res. 12 (2011), pp. 2825–2830.
- T. Fushiki, Estimation of prediction error by using K-fold cross-validation, Stat. Comput. 21 (2011), pp. 137–146. doi:https://doi.org/10.1007/s11222-009-9153-8.
- N. Chen, J. Chen, B. Yao, and Z. Li, QSAR study on antioxidant tripeptides and the antioxidant activity of the designed tripeptides in free radical systems, Molecules 23 (2018), pp. 1–12.
- Y.M. Zhang, Y.C. Wang, W.N. Zhou, Y.R. Fan, J.N. Zhao, L. Zhu, S. Lu, T. Lu, Y.D. Chen, and H.C. Liu, A combined drug discovery strategy based on machine learning and molecular docking, Chem. Biol. Drug Des. 93 (2019), pp. 685–699. doi:https://doi.org/10.1111/cbdd.13494.
- XGBoost 1.3.0: A python package index pypi. Available at https://pypi.python.org/pypi/xgboost/ (accessed October 2021).
- S. Bhagwati and M.I. Siddiqi, Deep neural network modeling based virtual screening and prediction of potential inhibitors for renin protein, J. Biomol. Struct. Dyn. (2020), pp. 1–14. doi:https://doi.org/10.1080/07391102.2020.1860825.
- H. Liu, W. Zhang, Y. Song, L. Deng, and S. Zhou, HNet-DNN: Inferring new drug-disease associations with deep neural network based on heterogeneous network features, J. Chem. Inf. Model. 60 (2020), pp. 2367–2376. doi:https://doi.org/10.1021/acs.jcim.9b01008.
- D. Kingma and J. Ba, Adam: A method for stochastic optimization, Comput. Sci. (2014), pp. 1–15.
- L. Deng, Y. Cai, W. Zhang, W. Yang, B. Gao, and H. Liu, Pathway-guided deep neural network toward interpretable and predictive modeling of drug sensitivity, J. Chem. Inf. Model. 60 (2020), pp. 4497–4505. doi:https://doi.org/10.1021/acs.jcim.0c00331.
- Torch 1.7.1. Available at https://pytorch.org/ (accessed October 2021).
- S. Ioffe and C. Szegedy, Batch normalization: Accelerating deep network training by reducing internal covariate shift, Int. Conf. Mach. Learn. 37 (2015), pp. 448–456.
- Y. Zhou, S. Cahya, S.A. Combs, C.A. Nicolaou, J. Wang, P.V. Desai, and J. Shen, Exploring tunable hyperparameters for deep neural networks with industrial ADME data sets, J. Chem. Inf. Model. 59 (2019), pp. 1005–1016. doi:https://doi.org/10.1021/acs.jcim.8b00671.
- X. Wang, M. Liu, L. Zhang, Y. Wang, Y. Li, and T. Lu, Optimizing pharmacokinetic property prediction based on integrated datasets and a deep learning approach, J. Chem. Inf. Model. 60 (2020), pp. 4603–4613. doi:https://doi.org/10.1021/acs.jcim.0c00568.
- T.I. Netzeva, A. Worth, T. Aldenberg, R. Benigni, M.T. Cronin, P. Gramatica, J.S. Jaworska, S. Kahn, G. Klopman, C.A. Marchant, G. Myatt, N. Nikolova-Jeliazkova, G.Y. Patlewicz, R. Perkins, D. Roberts, T. Schultz, D.W. Stanton, J.J. van de Sandt, W. Tong, G. Veith, and C. Yang, Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52, Altern. Lab. Anim. 33 (2005), pp. 155–173. doi:https://doi.org/10.1177/026119290503300209.
- W. Klingspohn, M. Mathea, A. Ter Laak, N. Heinrich, and K. Baumann, Efficiency of different measures for defining the applicability domain of classification models, J. Cheminform. 9 (2017), pp. 1–44. doi:https://doi.org/10.1186/s13321-017-0230-2.
- I. Sushko, S. Novotarskyi, R. Korner, A.K. Pandey, V.V. Kovalishyn, V.V. Prokopenko, and I.V. Tetko, Applicability domain for in silico models to achieve accuracy of experimental measurements, J. Chemom. 24 (2010), pp. 202–208. doi:https://doi.org/10.1002/cem.1296.
- G. Tu, Z. Qin, D. Huo, S. Zhang, and A. Yan, Fingerprint-based computational models of 5-lipo-oxygenase activating protein inhibitors: Activity prediction and structure clustering, Chem. Biol. Drug. Des. 96 (2020), pp. 931–947. doi:https://doi.org/10.1111/cbdd.13657.
- Y. Wu, D. Huo, G. Chen, and A. Yan, SAR and QSAR research on tyrosinase inhibitors using machine learning methods, SAR QSAR Environ. Res. 32 (2021), pp. 85–110. doi:https://doi.org/10.1080/1062936X.2020.1862297.
- J.H. Kim, Estimating classification error rate: Repeated cross-validation, repeated hold-out and bootstrap, Comput. Stat. Data An. 53 (2009), pp. 3735–3745. doi:https://doi.org/10.1016/j.csda.2009.04.009.
- D. Bajusz, A. Racz, and K. Heberger, Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations?, J. Cheminform. 7 (2015), pp. 1–20. doi:https://doi.org/10.1186/s13321-015-0069-3.
- WEKA 3. Available at https://www.cs.waikato.ac.nz/ml/weka/ (accessed April 2022).
- P.C. Sathler, M. Santana, A.L. Lourenco, C.R. Rodrigues, P. Abreu, L.M. Cabral, and H.C. Castro, Human thromboxane synthase: Comparative modeling and docking evaluation with the competitive inhibitors Dazoxiben and Ozagrel, J. Enzym. Inhib. Med. Ch. 29 (2014), pp. 527–531. doi:https://doi.org/10.3109/14756366.2013.817403.
- W.C. Chao, J.F. Lu, J.S. Wang, H.C. Yang, T.A. Pan, S.C.W. Chou, L.H. Wang, and P.T. Chou, Probing ligand binding to thromboxane synthase, Biochemistry 52 (2013), pp. 1113–1121. doi:https://doi.org/10.1021/bi301400t.
- P.N. Sekhar, L.A. Reddy, M. De Maeyer, K.P. Kumar, Y.S. Srinivasulu, M.S.L. Sunitha, I.S.N. Sphoorthi, G. Jayasree, A.M. Rao, V.S. Kothekar, P.V.B.S. Narayana, and P.B.K. Kishor, Genome wide analysis and comparative docking studies of new diaryl furan derivatives against human cyclooxygenase-2, lipoxygenase, thromboxane synthase and prostacyclin synthase enzymes involved in inflammatory pathway, J. Mol. Graph. Model. 28 (2009), pp. 313–329. doi:https://doi.org/10.1016/j.jmgm.2009.08.010.